The BRAF mutation affects serine-threonine kinase BRAF and is found in ~40–60% of melanoma [42], while the NRAS mutation affects the RAS protein responsible for activating the signaling pathways that control cell proliferation, differentiation and survival [43]. The gene discussed is BRAF; the disease is melanoma.